22nd Century Group (Nasdaq: XXII) has acquired GVB Biopharma. Read the press release here
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
01/24/23 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
3 |
11/21/22 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
3 |
11/17/22 | 3 | Initial statement of beneficial ownership of securities |
![]() |
2 | |
11/17/22 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
2 |
11/08/22 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
![]() |
![]() ![]() ![]() |
45 |
11/08/22 | 8-K | Current report filing |
![]() |
![]() ![]() ![]() |
35 |
09/22/22 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
09/15/22 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
![]() |
10 | |
09/14/22 | EFFECT | Notice of Effectiveness |
![]() |
1 | |
09/12/22 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
![]() |
1 |